Related Experiment Video
Updated: May 31, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Recombinant tissue plasminogen activator for the treatment of acute ischemic stroke
1Department of Pharmacy Services, Baylor University Medical Center at Dallas.
Abstract:
The use of recombinant tissue plasminogen activator (rtPA) has been the standard of care for treatment of acute ischemic stroke for several years. Studies evaluating the efficacy, safety, and optimal timing of rtPA use are ongoing. Recently, results of new studies led to expansion of the short timeframe from stroke symptom onset in which a patient can receive this treatment. Additionally, more data are available to support the current goals of administration of rtPA to eligible patients as quickly as possible, as earlier treatment has been proven to improve outcomes.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Clot Retraction and Fibrinolysis
Transient Ischemic Attack l: Introduction
Ischemic Stroke l: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

